Lupin Limited has informed the Exchange that Board of Directors at its meeting held on May 14, 2025, recommended Final Dividend of Rs. 12 per equity share i.e. 600 % of the Face Value of Rs. 2/ Each Fully Paid Up for the Financial Year Ended March 31, 2025.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin's Board approved audited financial results for Q4 and FY ended March 31, 2025, alongside recommending a final dividend of Rs. 12 per share (600% on face value of Rs. 2), totalling Rs. 5,478.8 million, subject to shareholder approval at the AGM. Standalone revenue from operations grew 15.7% to Rs. 169,675 million while net profit jumped 70.8% to Rs. 39,729.6 million, pushing EPS to Rs. 87.10 from Rs. 51.10. Consolidated revenue rose 13.5% to Rs. 227,079 million and consolidated PAT climbed 70.8% to Rs. 33,062.6 million, with EPS at Rs. 71.95. The results include exceptional items of Rs. 772.2 million for impairment of investments in two subsidiaries, a Rs. 856.1 million (USD 10 million) provision for ongoing disputes, and a Rs. 750.5 million settlement related to the Glumetza litigation. The company is also transferring its OTC India business and API R&D business to wholly-owned subsidiaries on a slump sale basis.
Strong double-digit revenue growth and a sharp ~71% jump in profits reflect margin expansion and operational improvement, which should support the stock; the Rs. 12 dividend offers a healthy payout to shareholders awaiting AGM approval.